Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 7680 results

  1. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development [GID-TA11402] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460

    Awaiting development [GID-TA11534] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463

    Awaiting development [GID-TA11590] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Awaiting development [GID-TA11467] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development [GID-TA11428] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]

    In development [GID-TA11164] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Duplicate

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  11. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284

    In development [GID-TA11334] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development [GID-TA11058] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  13. Osteoporosis

    Awaiting development [GID-QS10188] Expected publication date: TBC

    Quality standard
    Awaiting development

  14. Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

    Awaiting development [GID-TA11576] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development